Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission (EC) has granted orphan drug status to AiCuris' human cytomegalovirus (HCMV) drug AIC246, following the positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
Subscribe to our email newsletter
AIC246 is currently is in Phase IIb trial.
AiCuris CEO Rubsamen-Schaeff said the orphan drug status will also support the company in the development of AIC246 as it gives easier access to scientific support by the agencies.
AiCuris CSO Holger Zimmermann said they believe that they are developing a therapy that will prove to be both effective and safe and at the same time remains efficacious, if resistance has developed against the marketed drugs.